Cell & Gene: The Podcast
CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D.
Feb 27, 2025
Omkar Kawalekar, Ph.D., a Senior Manager and NextGen Therapies Manufacturing & Supply Chain Lead at Deloitte Consulting, dives into the future of cell and gene therapy manufacturing. He discusses how distributed manufacturing models can tackle capacity issues and supply chain threats. Omkar emphasizes the role of automation in minimizing variability between batches and the significance of digital technologies in optimizing production. He explores vital decisions for CGT companies regarding in-house versus CDMO partnerships, providing insights on efficiency and innovation.
28:42
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Distributed manufacturing models enhance patient access to cell therapies by addressing capacity constraints and ensuring timely delivery through coordinated production sites.
- The integration of automation and digital technologies in manufacturing processes is crucial for reducing variability and optimizing efficiency in cell and gene therapy production.
Deep dives
The Evolution of Distributed Manufacturing in Cell Therapies
Distributed manufacturing in cell therapies involves a network of centrally coordinated sites spread across various locations. This model differs from decentralized manufacturing, which operates multiple independent sites, and point of care manufacturing, where therapies are produced at the treatment location. Distributed manufacturing aims to enhance patient access to life-saving therapies by increasing scalability and flexibility, which is essential given the demand fluctuations in cell and gene therapies. By employing multiple production sites, companies can better manage capacity constraints and ensure prompt delivery of therapies to patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
